Tyagarajan Seshu
SEC CIK 1923794 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | See Remarks | 76.9K | $25.1K | $1.20M | 15 | 2022-11-28 | 2026-08-17 |
Most active insiders at CADL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Tak Paul Peter | CEO, Dir | — | $3.16M |
| 2 | Manning Paul B | Dir | $3.00M | — |
| 3 | Barone Francesca | CSO | — | $235.8K |
| 4 | Tyagarajan Seshu | CTO | — | $154.2K |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-19 16:30 | 2026-08-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $12.00 | -7,000 | 76.9K | -8% | -$84.0K |
| T | 2026-07-01 16:22 | 2026-06-29 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $10.02 | -7,000 | 83.9K | -8% | -$70.2K |
| 2025-06-26 | 2025-06-25 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | A - Grant | $4.67 | +5,353 | 90.9K | +6% | +$25.0K | |
| DAT | 2025-03-20 | 2025-03-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale+OE | $8.82 | -31.3K | 85.5K | -27% | -$275.9K |
| DAT | 2025-03-20 | 2025-03-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | M - OptEx | $1.29 | +20.0K | 116.8K | +21% | +$25.8K |
| DT | 2025-03-19 | 2025-03-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $8.82 | -31.3K | 85.5K | -27% | -$275.9K |
| 2025-01-17 | 2025-01-15 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $7.23 | -14.3K | 96.8K | -13% | -$103.5K | |
| 2025-01-10 | 2025-01-08 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $8.22 | -14.5K | 111.1K | -12% | -$119.6K | |
| 2024-12-03 | 2024-11-29 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $4.56 | -20.4K | 125.7K | -14% | -$93.0K | |
| 2024-07-19 | 2024-07-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $6.47 | -14.9K | 146.0K | -9% | -$96.1K | |
| 2024-07-15 | 2024-07-11 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $5.97 | -13.3K | 160.9K | -8% | -$79.6K | |
| 2023-11-30 | 2023-11-28 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | F - Tax | $0.9 | -17.3K | 174.2K | -9% | -$15.6K | |
| 2023-11-28 | 2023-11-26 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | A - Grant | $0.00 | +104.5K | 191.6K | +120% | $0 | |
| M | 2022-12-12 | 2022-12-08+ | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | P - Purchase | $1.88 | +13.4K | 3,000 | New | +$25.1K |
| 2022-11-30 | 2022-11-28 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | See Remarks | A - Grant | $0.00 | +73.7K | 73.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations